Jane Street Group LLC Sells 13,210 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jane Street Group LLC trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 84.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,396 shares of the medical instruments supplier's stock after selling 13,210 shares during the quarter. Jane Street Group LLC's holdings in LeMaitre Vascular were worth $221,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in shares of LeMaitre Vascular during the fourth quarter valued at $14,900,000. Rockefeller Capital Management L.P. purchased a new position in shares of LeMaitre Vascular during the fourth quarter valued at $7,787,000. Segall Bryant & Hamill LLC purchased a new position in shares of LeMaitre Vascular during the fourth quarter valued at $5,446,000. Invesco Ltd. increased its stake in shares of LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after buying an additional 58,720 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of LeMaitre Vascular by 45.9% during the fourth quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock valued at $13,590,000 after buying an additional 46,430 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $83.40 on Friday. The company has a fifty day moving average of $83.73 and a two-hundred day moving average of $91.24. The stock has a market capitalization of $1.88 billion, a PE ratio of 45.57, a P/E/G ratio of 2.22 and a beta of 0.83. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the company earned $0.44 earnings per share. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is 40.40%.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 76,868 shares of the firm's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the sale, the chief executive officer now owns 1,796,783 shares of the company's stock, valued at approximately $154,146,013.57. The trade was a 4.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 102,009 shares of company stock worth $8,721,836 over the last three months. Insiders own 9.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on LMAT shares. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital lifted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Finally, Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $97.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.